Breakthrough in cardiac surgery with investment in AMT Medical

AMT's Elana Heart Bypass technology enables the creation of bypasses without opening the chest cavity or stopping the heart. This allows the procedure to be performed more quickly, safely, and with fewer complications. Thanks to a patented clip and precision laser, blood vessels can be connected entirely without sutures. Additionally, the technology is compatible with surgical robots, marking a breakthrough in the scalability and standardisation of minimally invasive cardiac surgery.

The technology shows great promise for a broad group of patients – particularly for elderly individuals who are often excluded from open-heart surgery. "We see AMT as a game-changer that not only improves outcomes for patients but also reduces pressure on the healthcare system," says Koen van Breugel, senior investment manager at Invest-NL. "This technology makes minimally invasive cardiac surgery more accessible, safer, and scalable – exactly the kind of system innovation we believe in."

With this funding, Invest-NL is helping AMT Medical obtain CE marking, conduct clinical studies both domestically and internationally, and prepare for market introduction. The first results from ongoing clinical research are expected by the end of 2025.

The investment aligns with our mission to contribute to a healthcare system that remains affordable, staffable, and accessible in the future.